drugset / Trial / NCT00272701

Esomeprazole in PPI Failures - IMPROVE

NCT00272701

Phase 4 Completed 450 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess how PPI treated GERD patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation of esomeprazole 40 mg compared to pre-study PPI treatment.

Timeline

Start
2005-12
Primary completion
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg